Dr. Robert Kyle, a leading myeloma physician, researcher, and professor at the Mayo Clinic, spoke with The Myeloma Beacon about his approach to treating multiple myeloma patients; participation in clinical trials; many of the key issues for myeloma patients and physicians, including conventional and alternative treatment options; and the future of personalized medicine.

This article is the second part of a two-part series based on the Beacon’s conversations with Dr. Kyle. It will cover the role of clinical trials and key issues in the treatment of multiple myeloma as well as promising …

Preliminary re­­sults from an on­go­ing Phase 1/2 clin­i­cal trial sug­gest that elotuzumab, in com­bi­na­tion with Revlimid (lena­lido­mide) and low-dose dexamethasone (Decadron), may have po­ten­tial in the treat­ment of mul­ti­ple myeloma. The findings were pre­sented at the American Society of He­ma­tol­ogy’s 51^st Annual Meeting at the beginning of last month.

Dr. Ravi Vij from the Uni­ver­sity of Washington in St. Louis, co-author of the study, remarked, “The trial showed very high rates of re­sponse when elotuzumab is given in com­bi­na­tion with Revlimid.”

Elotuzumab is a new drug that is cur­rently …

The 2009 American Society of Hematology (ASH) Meeting showcased several presentations on Zolinza (vorinostat), a histone deacetylase inhibitor developed by Merck Pharmaceuticals that is currently investigated for the treatment of multiple myeloma.

Zolinza alters the way a cancer cell’s DNA creates proteins, which is important in cancer treatment because such a drug can slow down cell proliferation, minimize mutations in DNA and control cell death.

Zolinza With Revlimid And Dexamethasone

Preliminary data from an ongoing Phase 1 study suggest that the combination treatment of Zolinza, Revlimid (lenalidomide) and …

Results from recent Phase 1/2 clinical trials show that a perifosine, Velcade (bortezomib) and dexamethasone (Decadron) combination treatment is safe and effective for relapsed and refractory multiple myeloma. Perifosine is an alkyl-phosphocholine compound that controls cell division, cell growth and cell death, and is currently investigated for the treatment of multiple myeloma. Researchers presented their findings on December 5 at the American Society of Hematology’s 51^st Annual Meeting.

“Great meeting—lots of exciting new developments for multiple myeloma,” wrote Dr. Paul Richardson, lead researcher in the study, in an …

A drug combination including Revlimid (lenalidomide) as both an induction and maintenance therapy increases progression-free survival in newly diagnosed multiple myeloma patients over the age of 65 years, new Phase 3 research suggests. Researchers presented the preliminary results of the MM-015 clinical trial on December 7 at the 51st annual meeting of the American Society of Hematology (ASH) in New Orleans.

Currently, Revlimid is only approved in combination with dexamethasone (Decadron) to treat relapsed multiple myeloma patients, according to the United States Food and Drug Administration. This trial’s findings …

Carfilzomib, which is a proteasome inhibitor under devel­op­ment as a treat­ment for multiple myeloma, has recently been shown to be a safe and effective treat­ment for myeloma patients with kidney failure, chromosomal ab­nor­mal­i­ties, or periph­eral neu­rop­athy. These results will be presented at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans December 5 through 8.

Additionally, ASH presenters will examine the effects of car­filz­o­mib in patients who have pre­vi­ously been treated with Velcade (bor­tez­o­mib) and in patients who are receiving car­filz­o­mib in com­bi­na­tion with Revlimid …

Preliminary results from several clinical trials testing carfilzomib (Kyprolis) for the treat­ment of multiple myeloma will be presented at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans December 5 through 8.

Carfilzomib, a proteasome inhibitor, is under devel­op­ment as a treat­ment for re­lapsed or refractory multiple myeloma. It is cur­rently in Phase 2 of clinical testing, which means that its safety and efficacy are being studied.

The ASH presenters will examine the effects of car­filz­o­mib in patients who have pre­vi­ously been treated with Velcade (bor­tez­o­mib); …